STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target
Nearly two decades ago, a small company called Amylin Pharmaceuticals saw that its first commercial…
Category: Eli Lilly
STAT+: At major cardiology conference, Wegovy’s the word
LONDON — When Europe’s largest cardiology conference opened here this past Friday, one of the…
Jim Wilson’s next venture, a surprise startup shutdown, & Lilly’s Zepbound strategy
What’s behind the “great abandonment” in gene therapy R&D? How does a startup spend $213…
Is the GLP-1 party running down for Hims, and a study for the weekend
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in…
STAT+: The weight loss drug shortage is driving patients to Hims. What happens when the shortage ends?
Hims & Hers, one of the largest publicly traded telehealth companies in the country, has…
Eli Lilly’s lauded discount of its obesity drug Zepbound comes with caveats
Eli Lilly garnered widespread praise Tuesday for launching discounted versions of its blockbuster obesity drug…
STAT+: Lilly launches Zepbound vials in move that could ease supply constraints
Eli Lilly said Tuesday that it will start providing low-dose vials of its obesity drug…
STAT+: Will the FTC challenge a deal that would give Novo Nordisk control of some Catalent plants?
As the Federal Trade Commission scrutinizes the pharmaceutical industry, there is growing debate about whether…
STAT+: Eli Lilly’s billions: Can the world’s most valuable pharma company keep inventing drugs at this pace?
On Tuesday, Eli Lilly unveiled a towering 346,000-square-foot laboratory in Boston’s Seaport District, a building…
STAT+: Eli Lilly boosts 2024 revenue guidance by $3 billion on Mounjaro, Zepbound sales
Eli Lilly raised its full-year revenue guidance by $3 billion, driven by massive sales of…
STAT+: Novo Nordisk pulls filings for Wegovy in heart failure as it waits for cardiovascular outcomes data
Novo Nordisk is pulling its regulatory submissions to expand the use of its obesity drug…
STAT+: North Carolina urges HHS to license Novo and Lilly obesity drugs as a way to lower costs
Frustrated by the lack of access to expensive weight loss drugs, North Carolina officials are…
STAT+: Eli Lilly’s obesity drug Zepbound shows benefits in heart failure patients
Eli Lilly’s obesity drug Zepbound cut the risk of complications and improved symptoms in patients…
As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them
Around the world, patients suddenly can’t find enough of the insulins made by companies they…
STAT+: Novo Nordisk’s weekly insulin rejected by FDA
The Food and Drug Administration rejected Novo Nordisk’s weekly insulin for the treatment of diabetes…
STAT+: Eli Lilly to acquire Morphic for $3.2 billion
Eli Lilly said Monday it will acquire Morphic Holding, a biotech developing a treatment for…
STAT+: FDA approves Eli Lilly’s early Alzheimer’s treatment
Eli Lilly’s early Alzhiemer’s treatment was approved by the Food and Drug Administration on Tuesday,…
STAT+: The biotech scorecard for the third quarter: 19 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third…
STAT+: Experts split on whether Eli Lilly’s Zepbound will hamper CPAP sales
Continuous positive airway pressure “is here to stay,” sleep medicine doctor Atul Malhotra declared in…
STAT+: FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted to a smaller group
Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental…
STAT+: Eli Lilly’s obesity drug Zepbound improved liver scarring in mid-stage MASH study
Eli Lilly’s blockbuster diabetes and obesity drug improved living scarring in a mid-stage study of…
STAT+: Bernie Sanders may have reached the limits of his pharma pressure campaign
WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him….
STAT+: Lilly’s weekly insulin works as well as daily products, new studies show
Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal…
STAT+: 4 burning questions about Amgen’s obesity drug, a potential Wegovy and Zepbound competitor
Amgen’s comments Thursday that it’s “very encouraged” by interim Phase 2 data for its obesity…
Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama
The removal of small amounts of brain tissue from desperately ill patients, done as part…
STAT+: Eli Lilly raises earnings guidance as Zepbound sales beat expectations
Eli Lilly raised its full-year guidance on Tuesday while it reported strong first-quarter sales of…
STAT+: The biotech scoreboard for the second quarter: 32 stock-moving events to watch
Here is STAT’s biotech scoreboard, our regular ledger of stock-moving biotech events, for the second…
STAT+: In surprise move, FDA calls for advisory committee on Lilly’s Alzheimer’s drug
In a surprise move, the Food and Drug Administration has called for a meeting of…
STAT+: Startup BioAge raises $170 million Series D for Zepbound combination therapy
A California biotech developing a combination therapy with the obesity drug Zepbound has raised a…
STAT+: Why Eli Lilly’s earnings didn’t quite live up to the hype
Eventually, the luckiest companies get to deal with a very particular problem: what to do…
STAT+: Eli Lilly reports tirzepatide MASH success during Q4 earnings
The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve…
STAT+: More patients are getting their meds online. Big Pharma wants in on the action
Since the pandemic, patients have become increasingly comfortable with getting their medications online. Direct-to-consumer telehealth…
STAT+: Structure Therapeutics GLP-1 pill cuts blood sugar, weight in early diabetes study
Structure Therapeutics said Monday that its experimental GLP-1 pill demonstrated a 1% lowering of blood…
STAT+: Here are the best biopharma CEOs of 2023
It’s that time of the year again when I recognize the Best Biopharma CEO of…
AMA urges coverage of obesity treatments as payers balk at costs
WASHINGTON – The American Medical Association called on insurance companies, employers, and government programs to…
STAT+: Eli Lilly’s chief scientist on new obesity drug data, gene editing, and a potential new heart drug
PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a…
Senator floats new models to manage costs of weight loss drugs like Ozempic
WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival…
STAT+: FDA approves Lilly ulcerative colitis treatment with a new approach to tamping down inflammation
The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a…
STAT+: In drug development, large pharma companies’ staying power provides them an edge, Lilly’s chief medical officer says
Among drugmakers, big pharma has a reputation of being stodgy and old-fashioned, while biotech startups…
STAT+: Why doesn’t everyone lose weight on Ozempic-type drugs? Researchers look for genetic clues
DALLAS — Treatments like Ozempic, Wegovy, and Mounjaro have been hailed for showing 15% to…
STAT+: The Ozempic panic: Why a market frenzy over new weight loss drugs defies logic
There’s a specter haunting Wall Street. It started in biotech, where companies making drugs for…
STAT+: Our expensive obesity drugs are worth it, Novo Nordisk and Eli Lilly argue in raft of studies
DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and…
STAT+: New obesity drugs are in the works trying to out-blockbuster Wegovy and Mounjaro
The exploding popularity of drugs like Wegovy and Mounjaro has propelled dozens of companies to…
STAT+: Here are the dozens of weight loss drugs in development to catch a booming market
The blazing success of weight loss drugs like Wegovy and Mounjaro has electrified the pursuit…
STAT+: Eli Lilly CEO donates big to Mike Pence presidential super PAC
WASHINGTON — David Ricks, who leads Eli Lilly, made a major early donation to a…
Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
Dateline City: KENILWORTH, N.J. & NEW YORK & INDIANAPOLIS Three leading biopharmaceutical companies have announced…